Dynacure Receives Orphan Drug Designation in the EU for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:33:31-08:00July 11, 2019|
Innovative modelling approach by Dynacure/ISMS results in the 1st peer reviewed study on quantification of the centronuclear myopathy patient population siteadmin2020-11-07T02:44:42-08:00August 31, 2018|
